Diversity and Inclusion (D&I) in clinical trials remains a key challenge faced by the healthcare industry today. While many life sciences companies are just beginning down the path of enrolling a more diverse population in their clinical trials, several organizations have already made substantial inroads into ensuring participation in clinical trials better reflects the intended therapy area’s real-world population.

Experts discuss key considerations for assessing and restructuring clinical trial designs and processes to achieve better representation of target populations, including:

1. Approaches to increasing D&I in clinical research and ways to evaluate how successful they are.
2. Engaging with external partners to identify and recruit a diverse target patient population.
3. Trends in regulatory D&I requirements.